“I’m delighted that we have had a huge success in breast cancer and have moved to colon cancer and prostate cancer. We really just have to do better, though, before I would say, ‘we are really committed to precision medicine’ because the map I just outlined wouldn’t suggest we are putting our money where our mouth is as a country.” –Kimberly Popovits
“We know what we pay for, but we don’t necessarily know what is happeing when the diagnosis happens, when the decision happens. So I can’t necessarily go and tie a payment [to value] although I would potentially love to do that in the right circumstances with the right dataset.” –Paul Markovich